Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.78 |
| ▸ | PGR | P06401 | 7/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.58 |
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL6 | P05231 | 1/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.58 |
| ▸ | GLUL | P15104 | 1/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etiprednol Dicloacetate SCHEMBL13650061 | 1.00 | NR3C1 (0.78) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Etiprednol Dicloacetate SCHEMBL20589422 | 1.00 | NR3C1 (0.78) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Etiprednol Dicloacetate SCHEMBL13379814 | 1.00 | NR3C1 (0.78) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Etiprednol Dicloacetate SCHEMBL1650565 | 1.00 | NR3C1 (0.78) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL8502600 | 0.94 | NR3C1 (0.71) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL7609828 | 0.93 | NR3C1 (0.81) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL8505831 | 0.93 | NR3C1 (0.70) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL7614787 | 0.93 | NR3C1 (0.72) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL7612201 | 0.92 | NR3C1 (0.68) | NR3C1PGRABCB11NR1I2ABCC3 | |
| SCHEMBL7611101 | 0.91 | NR3C1 (0.68) | NR3C1PGRABCB11NR1I2ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| US-20250312274-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-09 | — | — | US | claimed |
| US-20250302742-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-02 | — | — | US | claimed |
| EP-4531922-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2025-04-09 | — | — | EP | claimed |
| EP-4531920-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2025-04-09 | — | — | EP | claimed |
| EP-4531921-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2025-04-09 | — | — | EP | claimed |
| US-20250082588-A1 | PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-13 | — | — | US | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| WO-2024167694-A2 | PLACENTAL EXTRACELLULAR MATRICES FOR OCULAR DELIVERY OF OPHTHALMIC THERAPEUTIC AGENTS | CELULARITY INC. (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2023227783-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-30 | — | — | WO | claimed |
| WO-2023227781-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-30 | — | — | WO | claimed |
| WO-2023227782-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-30 | — | — | WO | claimed |
| US-20230347080-A1 | PRESSURED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | US | claimed |
| US-20230277451-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-09-07 | — | — | US | claimed |
| EP-4225267-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2023-08-16 | — | — | EP | claimed |
| US-20230080276-A1 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-16 | — | — | US | claimed |
| EP-4106722-A1 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.p.A. (IT) | 2022-12-28 | — | — | EP | claimed |
| WO-2022074183-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-04-14 | — | — | WO | claimed |
| EP-0902789-B1 | ANDROSTENE DERIVATIVES | SOFT DRUGS INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-5981517-A | FOR TREATING INFLAMMATIONS OF EYES, EARS, SKINS, INTESTINES, MOUTHS, ASTHMA, AND ARTHRITIS IN ANIMALS | SOFT DRUGS, INC. (US) | 1999-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | KDR, FLT4, FLT1 | NR3C1 71/4885PGR 149/4885ABCB11 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.